EXIT (2016):

* Investment Date & Round: Led Series B in March, 2011, with Sequoia Capital following (invested $12.5M)
* Initial Premoney Valuation: $14.1M
* Acquisition: Myriad Genetics in 2016
* Exit Value: 1) $70.5M, 2) $410M
* Return Multiple: ~6x

AssureX created a genetic test called Genesight that uses a small saliva sample and can tell what anti-depression, anti-psychotic, anti-anxiety or analgesic drug would work on any individual patient.

In the psychiatric and psychology areas, many patients do not respond to drugs, so the doctors in those fields have to use trial and error. In depression cases, the patient would often commit suicide before the doctor found that a drug wasn’t working. In addition, the proper dosage was also uncertain. AssureX was able to identify the genetics of a patient that revealed why some drugs work and others do not. The test is now being used by hundreds of thousands of patients every year.

Ted Driscoll met this Founder and served on the Board from the beginning through the exit.
​
“This is the future of pharma: pharmacogenomics. Every individual responds differently to different drugs. This is a key part of personalized medicine.”– Ted Driscoll